87 related articles for article (PubMed ID: 9335512)
1. A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102.
Gralow JR; Barlow WE; Lew D; Dammann K; Somlo G; Rinn KJ; Vogel SJ; Wong L; Livingston RB; Hortobagyi GN
Breast Cancer Res Treat; 2014 Jan; 143(2):351-8. PubMed ID: 24352574
[TBL] [Abstract][Full Text] [Related]
2. Taxanes for the treatment of metastatic breast cancer.
Gradishar WJ
Breast Cancer (Auckl); 2012; 6():159-71. PubMed ID: 23133315
[TBL] [Abstract][Full Text] [Related]
3. Weekly docetaxel in the treatment of metastatic breast cancer.
Palmeri L; Vaglica M; Palmeri S
Ther Clin Risk Manag; 2008 Oct; 4(5):1047-59. PubMed ID: 19209285
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel and epirubicin salvage regimen in relapsed anthracycline-sensitive metastatic breast cancer patients after anthracycline-containing adjuvant therapy.
Seo JH; Sung HJ; Park KH; Choi IK; Oh SC; Shin SW; Kim YH; Kim JS; Kim AR; Lee JB; Koo BH
Invest New Drugs; 2009 Feb; 27(1):67-73. PubMed ID: 18758689
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of docetaxel (Taxotere) as second-line chemotherapy in patients with metastatic breast cancer.
Baur M; van Oosterom AT; Diéras V; Tubiana-Hulin M; Coombes RC; Hatschek T; Murawsky M; Klink-Alakl M; Hudec M; Dittrich C
J Cancer Res Clin Oncol; 2008 Feb; 134(2):125-35. PubMed ID: 17636328
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate.
Amat S; Bougnoux P; Penault-Llorca F; Fétissof F; Curé H; Kwiatkowski F; Achard JL; Body G; Dauplat J; Chollet P
Br J Cancer; 2003 May; 88(9):1339-45. PubMed ID: 12778058
[TBL] [Abstract][Full Text] [Related]
7. Risks and benefits of taxanes in breast and ovarian cancer.
Michaud LB; Valero V; Hortobagyi G
Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy.
Valero V
Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-11-S13-18. PubMed ID: 9335512
[TBL] [Abstract][Full Text] [Related]
9. Review of docetaxel (Taxotere), a highly active new agent for the treatment of metastatic breast cancer.
Ravdin PM; Valero V
Semin Oncol; 1995 Apr; 22(2 Suppl 4):17-21. PubMed ID: 7740326
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel in anthracycline-resistant metastatic breast cancer.
Hui YF; Ignoffo RJ
Cancer Pract; 1997; 5(2):124-7. PubMed ID: 9110651
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel in combination chemotherapy for metastatic breast cancer.
Khayat D; Antoine E
Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-19-S13-26. PubMed ID: 9335513
[TBL] [Abstract][Full Text] [Related]
12. Single-agent docetaxel (Taxotere) in randomized phase III trials.
Burris HA
Semin Oncol; 1999 Jun; 26(3 Suppl 9):1-6. PubMed ID: 10426452
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer.
van Oosterom AT
Semin Oncol; 1995 Dec; 22(6 Suppl 13):22-8. PubMed ID: 8604449
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
